Next-generation sequencing reveals novel resistance mechanisms and molecular heterogeneity in EGFR-mutant non-small cell lung cancer with acquired resistance …
Objectives Despite initial responses to epidermal growth factor receptor tyrosine kinase
inhibitors (EGFR-TKIs) in EGFR mutant non-small cell lung cancer, patients invariably …
inhibitors (EGFR-TKIs) in EGFR mutant non-small cell lung cancer, patients invariably …
[HTML][HTML] Targeted sequencing identifies genetic alterations that confer primary resistance to EGFR tyrosine kinase inhibitor (Korean Lung Cancer Consortium)
SM Lim, HR Kim, EK Cho, YJ Min, JS Ahn, MJ Ahn… - Oncotarget, 2016 - ncbi.nlm.nih.gov
Background Non-small-cell lung cancer (NSCLC) patients with activating epidermal growth
factor receptor (EGFR) mutations may exhibit primary resistance to EGFR tyrosine kinase …
factor receptor (EGFR) mutations may exhibit primary resistance to EGFR tyrosine kinase …
[HTML][HTML] Potential resistance mechanisms revealed by targeted sequencing from lung adenocarcinoma patients with primary resistance to epidermal growth factor …
J Zhong, L Li, Z Wang, H Bai, F Gai, J Duan… - Journal of Thoracic …, 2017 - Elsevier
Introduction EGFR tyrosine kinase inhibitors (TKIs) have greatly improved the prognosis of
lung adenocarcinoma. However, approximately 5% to 10% of patients with lung …
lung adenocarcinoma. However, approximately 5% to 10% of patients with lung …
[HTML][HTML] Mutational profiling of non-small-cell lung cancer patients resistant to first-generation EGFR tyrosine kinase inhibitors using next generation sequencing
Y Jin, Y Shao, X Shi, G Lou, Y Zhang, X Wu, X Tong… - Oncotarget, 2016 - ncbi.nlm.nih.gov
Patients with advanced non-small-cell lung cancer (NSCLC) harboring sensitive epithelial
growth factor receptor (EGFR) mutations invariably develop acquired resistance to EGFR …
growth factor receptor (EGFR) mutations invariably develop acquired resistance to EGFR …
Amplification of EGFR wild-type alleles in non–small cell lung cancer cells confers acquired resistance to mutation-selective EGFR tyrosine kinase inhibitors
S Nukaga, H Yasuda, K Tsuchihara, J Hamamoto… - Cancer research, 2017 - AACR
EGFR-mutated lung cancers account for a significant subgroup of non–small cell lung
cancers overall. Third-generation EGFR tyrosine kinase inhibitors (TKI) are mutation …
cancers overall. Third-generation EGFR tyrosine kinase inhibitors (TKI) are mutation …
[HTML][HTML] Identification of genetic alterations associated with primary resistance to EGFR-TKIs in advanced non-small-cell lung cancer patients with EGFR sensitive …
F Wang, XY Diao, X Zhang, Q Shao, YF Feng… - Cancer …, 2019 - Springer
Background Identification of activated epidermal growth factor receptor (EGFR) mutations
and application of EGFR-tyrosine kinase inhibitors (EGFR-TKIs) have greatly changed the …
and application of EGFR-tyrosine kinase inhibitors (EGFR-TKIs) have greatly changed the …
[HTML][HTML] Loss of activating EGFR mutant gene contributes to acquired resistance to EGFR tyrosine kinase inhibitors in lung cancer cells
K Tabara, R Kanda, K Sonoda, T Kubo, Y Murakami… - PLoS …, 2012 - journals.plos.org
Non-small-cell lung cancer harboring epidermal growth factor receptor (EGFR) mutations
attains a meaningful response to EGFR-tyrosine kinase inhibitors (TKIs). However, acquired …
attains a meaningful response to EGFR-tyrosine kinase inhibitors (TKIs). However, acquired …
Intrinsic resistance to EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer with activating EGFR mutations
J Wang, B Wang, H Chu, Y Yao - OncoTargets and therapy, 2016 - Taylor & Francis
Identifying activating EGFR mutations is a useful predictive strategy that helps select a
population of advanced non-small-cell lung cancer (NSCLC) patients for treatment with …
population of advanced non-small-cell lung cancer (NSCLC) patients for treatment with …
[HTML][HTML] Treatment strategies for non-small cell lung cancer harboring common and uncommon EGFR mutations: drug sensitivity based on exon classification, and …
R Kitadai, Y Okuma - Cancers, 2022 - mdpi.com
Simple Summary The advent of epidermal growth factor receptor (EGFR) tyrosine kinase
inhibitors (EGFR-TKIs) has led to a dramatic improvement in the prognosis of patients …
inhibitors (EGFR-TKIs) has led to a dramatic improvement in the prognosis of patients …
Heterogeneity in resistance mechanisms causes shorter duration of epidermal growth factor receptor kinase inhibitor treatment in lung cancer
K Suda, I Murakami, K Sakai, K Tomizawa, H Mizuuchi… - Lung cancer, 2016 - Elsevier
Objectives Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) are
used as a first line therapy for metastatic lung cancer harboring somatic EGFR mutation …
used as a first line therapy for metastatic lung cancer harboring somatic EGFR mutation …
相关搜索
- targeted sequencing primary resistance
- resistance mechanisms egfr tkis
- resistance mechanisms lung cancer
- molecular heterogeneity egfr tkis
- resistance mechanisms molecular heterogeneity
- acquired resistance egfr tyrosine
- acquired resistance kinase inhibitors
- intrinsic resistance egfr mutations
- egfr mutations lung cancer
- resistance mechanisms shorter duration
- genetic alterations egfr tkis
- shorter duration lung cancer
- acquired resistance egfr tkis
- acquired resistance molecular heterogeneity
- primary resistance egfr tkis
- resistance mechanisms targeted sequencing